-
1
-
-
8844233416
-
Chronic kidney disease: Prevention and treatment of common complications
-
Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician. 2004;70(10):1921-28.
-
(2004)
Am Fam Physician
, vol.70
, Issue.10
, pp. 1921-1928
-
-
Snively, C.S.1
Gutierrez, C.2
-
2
-
-
4644252248
-
State-specific trends in chronic kidney failure - United States, 1990-2001
-
Centers for Disease Control and Prevention
-
Centers for Disease Control and Prevention. State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep. 2004;53(39):918-20.
-
(2004)
MMWR Morb Mortal Wkly Rep
, vol.53
, Issue.39
, pp. 918-920
-
-
-
3
-
-
85039232111
-
Office of Disease Prevention and Health Promotion (ODPHP). Chronic kidney disease: A silent threat
-
U.S. Department of Health and Human Services, 18(4):1-6. Available at:, Accessed June 9
-
U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion (ODPHP). Chronic kidney disease: a silent threat. Prevention Report 2004;18(4):1-6. Available at: http://odphp.osophs. dhhs.gov/pubs/prevrpt/04Volume18/Iss4Vol18.pdf. Accessed June 9, 2006.
-
(2006)
Prevention Report 2004
-
-
-
4
-
-
4444252535
-
Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors
-
Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician. 2004;70(5):869-76.
-
(2004)
Am Fam Physician
, vol.70
, Issue.5
, pp. 869-876
-
-
Johnson, C.A.1
Levey, A.S.2
Coresh, J.3
Levin, A.4
Lau, J.5
Eknoyan, G.6
-
5
-
-
1642413198
-
Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
-
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-63.
-
(2004)
Arch Intern Med
, vol.164
, pp. 659-663
-
-
Keith, D.S.1
Nichols, G.A.2
Gullion, C.M.3
Brown, J.B.4
Smith, D.H.5
-
6
-
-
0034927743
-
Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994)
-
Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arc h Intern Med. 2001;161(9):1207-16.
-
(2001)
Arc h Intern Med
, vol.161
, Issue.9
, pp. 1207-1216
-
-
Coresh, J.1
Wei, G.L.2
McQuillan, G.3
-
7
-
-
0142138801
-
Chronic kidney disease and cardiovascular disease in the Medicare population
-
Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003;87:S24-S31.
-
(2003)
Kidney Int Suppl
, vol.87
-
-
Collins, A.J.1
Li, S.2
Gilbertson, D.T.3
Liu, J.4
Chen, S.C.5
Herzog, C.A.6
-
8
-
-
1642502319
-
National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
-
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47.
-
(2003)
Ann Intern Med
, vol.139
, Issue.2
, pp. 137-147
-
-
Levey, A.S.1
Coresh, J.2
Balk, E.3
-
9
-
-
0036176161
-
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
-
National Kidney Foundation
-
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
-
(2002)
Am J Kidney Dis
, vol.39
, Issue.2 SUPPL. 1
-
-
-
10
-
-
33646345152
-
-
K/DOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
-
K/DOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
-
-
-
-
11
-
-
5444255241
-
The prevalence of anemia in patients with chronic kidney disease
-
McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-10.
-
(2004)
Curr Med Res Opin
, vol.20
, Issue.9
, pp. 1501-1510
-
-
McClellan, W.1
Aronoff, S.L.2
Bolton, W.K.3
-
12
-
-
1542342375
-
the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: Final results from the PAERI study
-
McClellan W, Tran LL, the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: final results from the PAERI study. J Am Soc Nephrol. 2002;13:461A.
-
(2002)
J Am Soc Nephrol
, vol.13
-
-
McClellan, W.1
Tran, L.L.2
-
13
-
-
20144386857
-
Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the renal research institute-CKD study
-
Perlman R, Finkelstein F, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the renal research institute-CKD study. Am J Kidney Dis. 2005;45:658-66.
-
(2005)
Am J Kidney Dis
, vol.45
, pp. 658-666
-
-
Perlman, R.1
Finkelstein, F.2
Liu, L.3
-
15
-
-
0029959465
-
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
-
Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
-
(1996)
Am J Kidney Dis
, vol.28
, pp. 53-61
-
-
Foley, R.N.1
Parfrey, P.S.2
Harnett, J.D.3
-
16
-
-
0034256021
-
Hematocrit levels and associated Medicare expenditures
-
Collins AJ, Li S, Ebben J, et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36:282-93.
-
(2000)
Am J Kidney Dis
, vol.36
, pp. 282-293
-
-
Collins, A.J.1
Li, S.2
Ebben, J.3
-
17
-
-
31344445271
-
Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study
-
Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2):492-500.
-
(2006)
Am Heart J
, vol.151
, Issue.2
, pp. 492-500
-
-
Astor, B.C.1
Coresh, J.2
Heiss, G.3
Pettitt, D.4
Sarnak, M.J.5
-
18
-
-
31544469806
-
Association of anemia with outcomes in men with moderate and severe chronic kidney disease
-
Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69:560-64.
-
(2006)
Kidney Int
, vol.69
, pp. 560-564
-
-
Kovesdy, C.P.1
Trivedi, B.K.2
Kalantar-Zadeh, K.3
-
19
-
-
0028945387
-
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
-
Revicki D, Brown R, Feeny D, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54.
-
(1995)
Am J Kidney Dis
, vol.25
, pp. 548-554
-
-
Revicki, D.1
Brown, R.2
Feeny, D.3
-
20
-
-
9144264827
-
Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
-
Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121-32.
-
(2004)
Nephrol Dial Transplant
, vol.19
, Issue.1
, pp. 121-132
-
-
Locatelli, F.1
Pisoni, R.L.2
Combe, C.3
-
22
-
-
3042772186
-
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
-
Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94-111.
-
(2004)
Am J Kidney Dis
, vol.44
, Issue.1
, pp. 94-111
-
-
Pisoni, R.L.1
Bragg-Gresham, J.L.2
Young, E.W.3
-
23
-
-
85039203427
-
-
U.S. Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005:88-89.
-
U.S. Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005:88-89.
-
-
-
-
25
-
-
85039218842
-
-
U.S. Food and Drug Administration. List of orphan products designations and approvals (through December 31, 1999). Available at: http://www.fda.gov/ ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf. Accessed November 10, 2006.
-
U.S. Food and Drug Administration. List of orphan products designations and approvals (through December 31, 1999). Available at: http://www.fda.gov/ ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf. Accessed November 10, 2006.
-
-
-
-
26
-
-
0003775081
-
Committee for the Study of the Medicare End-Stage Renal Disease Program, Division of Health Care Services, Institute of Medicine
-
Rettig RA, Levinsky NG, eds, Washington DC: National Academy Press, Available at:, Accessed November 10
-
Rettig RA, Levinsky NG, eds. Committee for the Study of the Medicare End-Stage Renal Disease Program, Division of Health Care Services, Institute of Medicine. Kidney Failure and the Federal Government. Washington DC: National Academy Press, 1991. Available at: http://fermat.nap.edu/books/ 0309044324/html. Accessed November 10, 2006.
-
(1991)
Kidney Failure and the Federal Government
-
-
-
27
-
-
85039238240
-
-
The Biopharmaceuticals. FDA-approved biopharmaceutical drugs and vaccines [online]. Available at: http://www.accessexcellence.org/RC/AB/BA/ The_Biopharmaceuticals.html. Accessed November 10, 2006.
-
The Biopharmaceuticals. FDA-approved biopharmaceutical drugs and vaccines [online]. Available at: http://www.accessexcellence.org/RC/AB/BA/ The_Biopharmaceuticals.html. Accessed November 10, 2006.
-
-
-
-
28
-
-
85039234915
-
-
Columbia, co-transformation, commercialization & controversy: the Axel patent litigation. Harvard J Law Technol [online]. 2004;17(2):538-618. Available at: http://jolt.law.harvard.edu/articles/pdf/v17/ 17HarvJLTech583.pdf. Accessed November 10, 2006.
-
Columbia, co-transformation, commercialization & controversy: the Axel patent litigation. Harvard J Law Technol [online]. 2004;17(2):538-618. Available at: http://jolt.law.harvard.edu/articles/pdf/v17/ 17HarvJLTech583.pdf. Accessed November 10, 2006.
-
-
-
-
29
-
-
72449133295
-
-
U.S. Food and Drug Administration, online, Available at:, Accessed November 10
-
U.S. Food and Drug Administration. FDA approved drug products [online]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed November 10, 2006.
-
(2006)
FDA approved drug products
-
-
-
30
-
-
18744363354
-
Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease
-
Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63(5):327-34.
-
(2005)
Clin Nephrol
, vol.63
, Issue.5
, pp. 327-334
-
-
Ling, B.1
Walczyk, M.2
Agarwal, A.3
Carroll, W.4
Liu, W.5
Brenner, R.6
-
31
-
-
34548554731
-
Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-label, Australian study
-
Disney A, de Jersey P, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology. 2006;260(6):577-85.
-
(2006)
Nephrology
, vol.260
, Issue.6
, pp. 577-585
-
-
Disney, A.1
de Jersey, P.2
Kirkland, G.3
-
32
-
-
85039198339
-
An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis
-
In press
-
Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. In press.
-
J Intern Med
-
-
Agarwal, A.K.1
Silver, M.R.2
Reed, J.E.3
-
33
-
-
23144460027
-
PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
-
Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64(2):113-23.
-
(2005)
Clin Nephrol
, vol.64
, Issue.2
, pp. 113-123
-
-
Provenzano, R.1
Bhaduri, S.2
Singh, A.K.3
-
34
-
-
0036760032
-
Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia
-
Piccoli A, Malagoli A, Komninos G, et al. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol. 2002;15:565-74.
-
(2002)
J Nephrol
, vol.15
, pp. 565-574
-
-
Piccoli, A.1
Malagoli, A.2
Komninos, G.3
-
35
-
-
0037255238
-
Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease
-
Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106-11.
-
(2003)
Am J Nephrol
, vol.23
, pp. 106-111
-
-
Suranyi, M.G.1
Lindberg, J.S.2
Navarro, J.3
-
36
-
-
4644357756
-
Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration
-
Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004;24:453-60.
-
(2004)
Am J Nephrol
, vol.24
, pp. 453-460
-
-
Toto, R.D.1
Pichette, V.2
Navarro, J.3
-
37
-
-
14544272966
-
Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia
-
Available at:, Accessed October 30, 2006
-
Crémieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J Manag Care Pharm. 2004;10(6):531-37. Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-531-537.pdf. Accessed October 30, 2006.
-
(2004)
J Manag Care Pharm
, vol.10
, Issue.6
, pp. 531-537
-
-
Crémieux, P.Y.1
Fastenau, J.M.2
Kosicki, G.3
Piech, C.T.4
Fendrick, A.M.5
-
38
-
-
0036724388
-
Health care resource utilization and the impact of anemia management in patients with chronic kidney disease
-
London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40:539-48.
-
(2002)
Am J Kidney Dis
, vol.40
, pp. 539-548
-
-
London, R.1
Solis, A.2
Goldberg, G.A.3
Wade, S.4
Ryu, S.5
-
39
-
-
0037466966
-
Alcohol consumption and expenditures for underage drinking and adult excessive drinking
-
Foster SE, Vaughan RD, Foster WH, Califano JA Jr. Alcohol consumption and expenditures for underage drinking and adult excessive drinking. JAMA. 2003;289:989-95.
-
(2003)
JAMA
, vol.289
, pp. 989-995
-
-
Foster, S.E.1
Vaughan, R.D.2
Foster, W.H.3
Califano Jr., J.A.4
-
40
-
-
0017360990
-
The measurement of observer agreement for categorical data
-
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
-
(1977)
Biometrics
, vol.33
, pp. 159-174
-
-
Landis, J.R.1
Koch, G.G.2
-
41
-
-
48249153186
-
Intraclass correlations: Uses in assessing rater reliability
-
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin. 1979;86:420-28.
-
(1979)
Psychological Bulletin
, vol.86
, pp. 420-428
-
-
Shrout, P.E.1
Fleiss, J.L.2
-
42
-
-
0344874268
-
Impact of long-acting growth factors on practice dynamics and patient satisfaction
-
Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy. 2003;23(12 pt 2):101S-109S.
-
(2003)
Pharmacotherapy
, vol.23
, Issue.12 PART 2
-
-
Beveridge, R.A.1
Rifkin, R.M.2
Moleski, R.J.3
-
43
-
-
33748793448
-
Resource utilization and time commitment associated with correction of anaemia in cancer patients using epoetin alfa
-
Meehan KR, Tchekmedyian NS, Smith RE, Kallich J. Resource utilization and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Invest. 2006;26(10):593-601.
-
(2006)
Clin Drug Invest
, vol.26
, Issue.10
, pp. 593-601
-
-
Meehan, K.R.1
Tchekmedyian, N.S.2
Smith, R.E.3
Kallich, J.4
-
44
-
-
16244396713
-
Lessons learned in an urban CKD clinic
-
January
-
Crawford PW. Lessons learned in an urban CKD clinic. Nephrol News Issues. January 2005;43-48.
-
(2005)
Nephrol News Issues
, pp. 43-48
-
-
Crawford, P.W.1
-
45
-
-
23844476491
-
The role of the nurse practitioner in a CKD clinic
-
June
-
Calvin D, Roberts K. The role of the nurse practitioner in a CKD clinic. Nephrol News Issues. June 2005;26-29.
-
(2005)
Nephrol News Issues
, pp. 26-29
-
-
Calvin, D.1
Roberts, K.2
-
46
-
-
31544433971
-
Physician activities during time out of the examination room
-
Gilchrist V, McCord G, Schrop SL, et al. Physician activities during time out of the examination room. Ann Fam Med. 2005;3(6):494-99.
-
(2005)
Ann Fam Med
, vol.3
, Issue.6
, pp. 494-499
-
-
Gilchrist, V.1
McCord, G.2
Schrop, S.L.3
|